Due to the ongoing global pandemic Covid-19, ESO and ESMO have taken the decision to convert the 7th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology that was scheduled on 15-20 October 2021, into virtual ON-LINE MASTERCLASS.
We have done our best to design and build a new programme keeping the interactive, international, and collaborative Masterclass spirit which will include pre-recorded lectures, live sessions, clinical case presentations and direct contact with the Faculty members.
The online edition will be divided into two parts:
PART 1 (available from 16 September 2021)
Pre-recorded lectures will be organized into Modules based on tumour type and made available for participants to view in their own time one month before part 2. On completion of each module, participants will be given the opportunity to send questions related to the lectures, that will then be answered Live by the Faculty during part 2.
All modules from part 1 must be completed before part 2.
PART 2 (16-17 October 2021)
Online live event with lectures/ live discussion and participants’ case presentations to be discussed with top level experts. Selected participants will be paired and asked to prepare a clinical case together with a colleague from a different Country/Hospital.
ESO Chair: A. Eniu, CH
ESMO Chair: R. Obermannová, CZ
Host Chair: E. Vrdoljak, HR
Masterclass Coordinator: N. Pavlidis, GR
Advisers: T. Cufer, SI - G. Prager, AT
This residential programme has been designed for medical and clinical oncologists, who wish to improve their skills or those who are preparing for the national board or ESMO exam. The programme will expose participants to a full spectrum of issues in clinical and medical oncology from basic science to advanced knowledge of systemic therapy as well as in the multidisciplinary treatment approach. It is intended to cover all major topics of ESMO-ASCO curriculum on medical oncology.
The programme focuses on cancer pathology and molecular biology, pharmacology of anti-cancer drugs and on frequent cancers such as breast, lung, gastro-intestinal, gynaecological and head and neck cancer. Spotlight sessions will provide inside on state of the art approaches in melanoma, sarcoma, thyroid cancer and on palliative care. Furthermore, practical training will be offered in the frame of clinical case presentations, prepared and presented by the participants and faculty for an interactive discussion.
All participants will reside at the Masterclass venue and participation is mandatory throughout the course. At the end of each of the five days a learning self-assessment discussion with the chair of the course will be provided.
• To update the knowledge on basic science of clinical and medical oncology
• To enhance the competence and practical performance in systemic therapy of malignancies
• To enhance the competence and practical performance in multidisciplinary cancer care
• To update knowledge and get additional skills in supportive as well as palliative care
• To prepare for the board exam in clinical/medical oncology
THE MASTERCLASS IS:
• A five day residential, educational event
• Full immersion
• Clinically oriented
• Cancer biology/pathology
• Cancer genetics
• Pharmacology of anti-cancer drugs
• Breast cancer
• Gastro-intestinal tumours
• Gynaecological tumours
• Symptom management in gynaecological cancers
• Head and neck cancers
• Lung cancer and mesothelioma
• Genito-urinary cancers
• Palliative and supportive care
• Haematological malignancies
The Eastern Europe
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Joerg Beyer, Inselspital Bern, Oncology and Medicine Dpt., Bern, CH
Snezana Bosnjak, Institute of Oncology and Radiology of Serbia: ESMO Designated Centre of Integrated Oncology and Palliative Care, Supportive Oncology & Palliative Care Dpt., Belgrade, RS
Etienne Brain, Institut Curie, Medical Oncology Dpt., Saint-Cloud, FR
Maria-João Cardoso, Champalimaud Foundation, Breast Unit, Lisbon, PT
Stefano Cascinu, Università Vita-Salute San Raffaele, Dept. of Oncology/Hematology, Milano, IT
Tanja Cufer, University Clinic Golnik, Medical Oncology Unit, Golnik, SI
Alexandru Eniu, Riviera-Chablais Vaud-Valais, Interdisciplinary Oncology Service (SIC), Rennaz, CH
Fady B. Geara, American University of Beirut Medical Center, Dept. of Radiation Oncology, Riad El Solh, Beirut, LB
Dragana Jovanovic, Internal Medicine Clinic "Akta Medica", Dept. of Thoracic Oncology, Belgrade, RS
Izidor Kern, University Clinic Golnik, Dept. of Pathology, Golnik, SI
Salvador E. Martin Algarra, Clinica Universidad de Navarra, Medical Oncology Dept., Pamplona, Navarra, ES
Radka Obermannova, Masaryk Memorial Cancer Institute, Department Of Clinical Oncology, Brno, CZ
Tomislav Omrcen, University Hospital of Split, Medical School of Split, Oncology Dept., Split, HR
Demetris Papamichael, Bank of Cyprus Oncology Centre, Medical Oncology Dpt., Nicosia, CY
Nicholas Pavlidis, University Hospital of Ioannina, Medical Oncology Dpt., Ioannina, GR
Razvan Popescu, Tumor Center Aarau / Hirslanden Klinik Aarau, Medical Oncology / Hematology / Palliative Care Dpt., Aarau, CH
Marta Porebiak, SWPS University of Social Sciences and Humanities, Faculty of Psychology, Warsaw, PL
Gerald Prager, MUW, Department of Medicine 1, Vienna, AT
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Christos Sotiriou, Institut Jules Bordet, Breast Cancer Translational Research Laboratory J.C. Heuson-, Brussels, BE
Snjezana Tomic, Clinical Institute of Pathology KBC Split, Faculty of Medicine, Split, HR
Jan Baptist Vermorken, Antwerp University Hospital, Medical Oncology Dpt., Edegem, BE
Eduard Vrdoljak, Clinical Hospital Split, Medical School Split, Clinic Of Oncology And Radiotherapy, Split, HR
Christoph Zielinski, Central European Cooperative Oncology Group, Clinical Division of Oncology, Vienna, AT
Emanuele Zucca, Oncology Institute of Southern Switzerland (IOSI), Dept. of Medical Oncology, Bellinzona, CH
European School of Oncology - Bellinzona Office
Piazza Indipendenza 2
CH 6500 Bellinzona - Switzerland
Tel: +41 91 820 0952
Fax: +41 91 820 0953
The Masterclass will be held in English and translation will not be provided.
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
Applications for this event are closed.
PARTICIPANT’S PROFILE OF THE MASTERCLASS CANDIDATE
- Age between 30 and 40 years
- 2-3 years’ experience in medical oncology
- Involvement in scientific activities and clinical trials
- Fluency in English
HOW TO APPLY
Interested oncologists should apply online (at the top of this page) providing:
- Letter describing motivation for attending;
- Supporting letter from head of department or mentor;
- CV with list publications (if the list of publications is not provided, it will be assumed that no articles have been published)
- Clinical case (see below)
Priority will be given to candidates practicing in Eastern Europe and Balkan region countries.
CLINICAL CASE PRESENTATION
Submit an abstract of one page on the template (form available at the bottom of this page), describing a clinical case related to one of the subjects of the Masterclass (lung, genitourinary, breast, head-and-neck, gastrointestinal and gynaecological cancers). You will have to present your case at the Masterclass in format of a clinical grand round discussion. Please provide straightforward a case of your daily clinical practice - no uncommon or extremely rare cases. A maximum of 10 slides will be permitted containing:
- Diagnostic considerations
- Results, follow-up
- At least three questions proposed for discussion with the faculty
Participants will be asked to bring their personal laptop or tablet (wireless enabled) to the Masterclass as an event dedicated website will be created and all questionnaires and certificates will be accessible only from there. Any potential problems with meeting this request should be communicated to the secretariat as part of the application process.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and full board accommodation.
All participants will be expected to reside at the course venue and their full participation is compulsory throughout the course.
Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, supporting letter, Professional experience template and Abstract template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.
Part 1 Programme:
Part 1 has 6 blocks:
Block 1) Breast cancer
• Current controversies and challenges in breast cancer surgery – MJ Cardoso, PT
• Systemic treatment of early and advanced triple negative disease – G. Curigliano, IT
• Systemic treatment of HER2+ early and advanced disease – A. Eniu, CH
• Current controversies and challenges in radiotherapy – F. Geara, LB
• Preoperative chemotherapy and biologicals – N. Harbeck, DE
• Systemic treatment of luminal early and advanced breast cancer – O. Pagani, CH
• Molecular diagnostic pathology – G. Pruneri, IT
• Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines – F. Cardoso, PT
Block 2) Lung cancer
• Multimodality treatment of stage III NSCLC – R. Dziadziuszko, PL
• Molecular diagnostic pathology of NSCLC – I. Kern, SI
• Radiotherapy for NSCLC – F. Mc Donald, UK
• Systemic therapy for NSCLC with oncogenic driver mutations – C. Rolfo, US
• Systemic therapy for NSCLC without oncogenic driver mutations – S. Peters, CH
• Multimodality treatment of SCLC – R. Stahel, CH
• Surgery for early and locally advanced NSCLC – I. Schmitt-Opitz, CH
Block 3) Gastro-intestinal cancer
• Multimodal management of localized rectal cancer – A. Cervantes, ES
• Management of pancreatic cancer – S. De Dosso, CH
• Systemic treatment in advanced oesophageal and gastric cancer – F. Lordick, DE
• Adjuvant treatment in colon cancer – D. Papamichael, CY
• Liquid biopsies in GI tumors – F. Penault-Llorca, FR
• Optimal sequencing of systemic treatment for advanced hepatocellular carcinoma – A. Vogel, DE
• Systemic treatment in advanced colorectal cancer – E. van Cutsem, BE
Block 4) Gynaecological cancer
• Systemic treatment in cervical and endometrial cancer – C. Sessa, CH
• Systemic management of ovarian cancer and inhibitors of Parp – J.B. Vermorken, BE
• Guidelines in endometrial cancer – N. Colombo, IT
Block 5) Genitourinary cancer
• Management of testicular cancer – J. Beyer, CH
• First line endocrine therapy in endocrine sensitive prostate cancer – K. Fizazi, FR
• Localized prostate cancer – J. Khader, JO
• Systemic treatment of bladder cancer – H. Khaled, EG
• Treatment of endocrine resistant and refractory prostate cancer – X. Maldonado, ES
• Metastatic renal cancer: evidence-based treatment – N. Mottet, FR
Block 6) Spotlights
• Communication skills – F. Boyle, AU
• Ethics issues – S. Hurst-Majno, CH
• Breast cancer during pregnancy and fertility preservation – F.A. Peccatori, IT
• Early integration in oncology, supportive and palliative care – S. Peters, CH
• Cancer patients with COVID-19 – M. Garassino, IT
• Nutrition – J. Arends, DE
• Genomic Tests in clinical practice – F. Cardoso, PT
• Cancer in the elderly – M. Aapro, CH
• Immuno-oncology – H.A. Azim Jr., MX
• Parp inhibitors in BRCA mutation carriers – G. Curigliano, IT
• Brain tumours – R. Soffietti, IT
• Sarcomas – J.Y. Blay, FR
• Overview on head-and-neck tumours – S. Alfieri, IT
• Introduction to rare tumours – P. Casali, IT
• Modern management of melanoma – S. Martin Algarra, SP
Information on PART 2 (live weekend on 16-17 October) will follow soon.